HERE FOR YOUR INJECTION EXPERIENCE.

Training, tracking and preparation tips for managing your relapsing MS therapy with COPAXONE®.

Getting started with COPAXONE®

How to Start

An introduction to the free assistance that COPAXONE® is known for, with Teva’s Shared Solutions® and the original autoject®2 for glass syringe.

Pick your path
Preparation for COPAXONE® including before, during and after checklist

Preparation

Your complete before, during and after checklist, including training assistance for COPAXONE® patients throughout their MS experience.

Be prepared
COPAXONE® injection training for injections, guidance for travel, storing and disposal of supplies

COPAXONE® Injection Training

Convenient, in-person tips for injecting COPAXONE®, plus guidance for travel, storing and disposing of supplies.

Get expert tips
Injection tracking with Teva's tracking app for MS therapy

Injection Tracking

The COPAXONE iTracker® 2.0 is your app-y place for keeping MS therapy on track, from recording your injections to customizing information for your next appointment.

Download the app
COPAXONE® and generics, receiving the prescribed RMS prescription from your doctor

COPAXONE® and Generics

Information you need to know to ensure you receive your prescribed RMS medication from your doctor—and your pharmacy.

Know your rights

Use

COPAXONE® is a prescription medicine that is used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Important Safety Information

Do not use COPAXONE® if you are allergic to glatiramer acetate or mannitol.

Serious side effects may happen right after or within minutes after you inject COPAXONE® at any time during your course of treatment. Call your doctor right away if you have any of these immediate post-injection reaction symptoms including: redness to your cheeks or other parts of the body (flushing); chest pain; fast heart beat; anxiety; breathing problems or tightness in your throat; or swelling, rash, hives, or itching. If you have symptoms of an immediate post-injection reaction, do not give yourself more injections until a doctor tells you to.

You can have chest pain as part of an immediate post-injection reaction or by itself. This type of chest pain usually lasts a few minutes and can begin around 1 month after you start using COPAXONE®. Call your doctor right away if you have chest pain while using COPAXONE®.

Damage to the fatty tissue just under your skin’s surface (lipoatrophy) and, rarely, death of your skin tissue (necrosis) can happen when you use COPAXONE®. Damage to the fatty tissue under your skin can cause a “dent” at the injection site that may not go away. You can reduce your chance of developing these problems by following your doctor’s instructions for how to use COPAXONE® and choosing a different injection area each time you use COPAXONE®.

The most common side effects of COPAXONE® include redness, pain, swelling, itching, or a lump at the injection site; rash; shortness of breath; flushing; and chest pain.

Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of COPAXONE®. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please read the Patient Information in the full Prescribing Information.

Injections for 3-times-a-week COPAXONE® 40 mg must be at least 48 hours apart.

autoject®2 for glass syringe is a registered trademark of Owen Mumford, Ltd. Available by prescription only.
Apple is a registered trademark of Apple Inc. App Store is a service mark of Apple Inc.
Google Play and the Google Play logo are trademarks of Google LLC.

You are about to leave COPAXONE.com and enter a website operated by a third party.

Would you like to continue?

The information on this site is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States?